BioVersys Extends its Strategic Collaboration with GSK and Series C Round by CHF 12.3M
Shots:
- BioVersys and GSK have expanded their strategic collaboration to accelerate Alpibectir’s (BVL-GSK098; Small molecule) development. Beyond the present P-IIa, both companies will continue to develop Alpibectir in TB pulmonary and TB meningitis
- Under the collaboration, GSK will participate in BioVersys’ Series C extension with equity investment. Addition of CHF 12.3M from existing and new investors, results in total of CHF 44.9M in Series C round
- Additional funding will support clinical development of BioVersys’ portfolio includes BV100, a hospital antibiotic targeting Acinetobacter baumannii
Ref: BioVersys | Image: BioVersys
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
